Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaeamia

Lancet

Volumn 351, Issue 9098, 1998, Pages 263-

  Peterson, John C ^b   Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0013327427     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)78275-1     Document Type: Article

References (5)

1. 1 Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-81.
2. 2 Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-36.
3. 3 Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Euro J Clin Invest 1995; 25 (3): 176-81.
4. 4 Barnett PA, Spence KD, Manuck SB, Jennings JR. Psychological stress and the progression of carotid artery disease. J Hypertens 1997; 15: 49-55.
5. 5 Spence JD. Cerebral vascular consequences of hypertension: where do they lead? J Hypertens 1996; 14: S139-45.